DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for cartilage disease — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleCartilage disease maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for cartilage disease is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
lysine demethylase 4C (KDM4C) — KDM4C is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet iidrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KR7 · 1.9 Å · ligand FE (II) ION (FE2). Experimental structure, not a prediction.
What the evidence adds up to
Full-thickness knee cartilage defects have been treated with autologous chondrocyte transplantation since at least 1994. In the original study of 23 patients aged 14 to 48 with defects 1.6 to 6.5 cm², transplants eliminated locking and reduced pain and swelling in all patients initially. Two years after transplantation, 14 of 16 patients with femoral condylar transplants had good-to-excellent results; two required a second operation for severe central wear. For patellar transplants, results were excellent or good in only two of seven patients, fair in three, and poor in two; two required a second operation for severe chondromalacia. Biopsies showed hyaline cartilage appearance in 11 of 15 femoral transplants but only 1 of 7 patellar transplants.
A systematic review from 2021 evaluated the spheroid-based autologous chondrocyte implantation product approved in the European Union. The review included 20 publications (7 pre-/nonclinical, 13 clinical) and reported short- to mid-term safety and efficacy in both randomised trials with selected patients and routine treatment providing real-world data in more complex patients. Separately, an ex vivo human cartilage repair model using chondrocyte spheroids from 14 donors found that repair tissue formation varied among donors. Aggrecan protein expression in spheroids before implantation correlated positively with regeneration potential, suggesting aggrecan levels could serve as a surrogate potency assay.
A 2017 editorial on mesenchymal stem cell therapies for cartilage disorders noted that current management strategies have shown only modest success. Stem cell therapies were described as promising due to their differentiation and healing-support potential, but the editorial offered no clinical results. A 2016 review of surgical treatment for local femoral condyle defects covered marrow stimulation, autologous osteochondral mosaicplasty, and the use of chondrocyte and mesenchymal stem cell cultures, again without presenting new data.
A 2024 proteomic study of the infrapatellar fat pad in 53 patients who received surgical treatment for knee cartilage defects identified proteins differentially abundant in those with better clinical outcome. Downregulation of CILP-2 and MGST1 and upregulation of ACAN and PRG4 were associated with better outcome scores and MRI features. Pathways related to cell interaction, oxidation and matrix remodelling were altered. A 2025 review of tissue-engineered and cell-based therapies noted that approved products vary in manufacturing methods, cell types, and matrix use, and that each option has particular indications, benefits and limitations.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
New England Journal of Medicine · 1994 · 5527 citations · open access
Treatment of Deep Cartilage Defects in the Knee with Autologous Chondrocyte Transplantation
AbstractBACKGROUND: Full-thickness defects of articular cartilage in the knee have a poor capacity for repair. They may progress to osteoarthritis and require total knee replacement. We performed autologous chondrocyte transplantation in 23 people with deep cartilage defects in the knee. METHODS: The patients ranged in age from 14 to 48 years and had full-thickness cartilage defects that ranged in size from 1.6 to 6.5 cm2. Healthy chondrocytes obtained from an uninvolved area of the injured knee during arthroscopy were isolated and cultured in the laboratory for 14 to 21 days. The cultured chondrocytes were then injected into the area of the defect. The defect was covered with a sutured periosteal flap taken from the proximal medial tibia. Evaluation included clinical examination according to explicit criteria and arthroscopic examination with a biopsy of the transplantation site. RESULTS: Patients were followed for 16 to 66 months (mean, 39). Initially, the transplants eliminated knee locking and reduced pain and swelling in all patients. After three months, arthroscopy showed that the transplants were level with the surrounding tissue and spongy when probed, with visible borders. A second arthroscopic examination showed that in many instances the transplants had the same macroscopic appearance as they had earlier but were firmer when probed and similar in appearance to the surrounding cartilage. Two years after transplantation, 14 of the 16 patients with femoral condylar transplants had good-to-excellent results. Two patients required a second operation because of severe central wear in the transplants, with locking and pain. A mean of 36 months after transplantation, the results were excellent or good in two of the seven patients with patellar transplants, fair in three, and poor in two; two patients required a second operation because of severe chondromalacia. Biopsies showed that 11 of the 15 femoral transplants and 1 of the 7 patellar transplants had the appearance of hyaline cartilage. CONCLUSION: Cultured autologous chondrocytes can be used to repair deep cartilage defects in the femorotibial articular surface of the knee joint.
International Journal of Molecular Sciences · 2021 · 49 citations · open access
Role of Matrix-Associated Autologous Chondrocyte Implantation with Spheroids in the Treatment of Large Chondral Defects in the Knee: A Systematic Review
AbstractAutologous chondrocyte implantation (ACI) is a cell therapy for the treatment of focal cartilage defects. The ACI product that is currently approved for use in the European Union (EU) consists of spheroids of autologous matrix-associated chondrocytes. These spheroids are spherical aggregates of ex vivo expanded human autologous chondrocytes and their self-synthesized extracellular matrix. The aim is to provide an overview of the preclinical and nonclinical studies that have been performed to ensure reproducible quality, safety, and efficacy of the cell therapy, and to evaluate the clinical data on ACI with spheroids. A systematic review was performed to include all English publications on self-aggregated spheroids of chondrocytes cultured in autologous serum without other supplements. A total of 20 publications were included, 7 pre- and nonclinical and 13 clinical research publications. The pre- and nonclinical research publications describe the development from concept to in vivo efficacy and quality- and safety-related aspects such as biodistribution, tumorigenicity, genetic stability, and potency. The evaluation of clinical research shows short- to mid-term safety and efficacy for the ACI with spheroid-based treatment of cartilage defects in both randomized clinical trials with selected patients, as well as in routine treatment providing real-world data in more complex patients.
World Journal of Orthopedics · 2017 · 18 citations · open access
Update on mesenchymal stem cell therapies for cartilage disorders
AbstractCartilage disorders, including focal cartilage lesions, are among the most common clinical problems in orthopedic practice. Left untreated, large focal lesions may result in progression to osteoarthritis, with tremendous impact on the quality of life of affected individuals. Current management strategies have shown only a modest degree of success, while several upcoming interventions signify better outcomes in the future. Among these, stem cell therapies have been suggested as a promising new era for cartilage disorders. Certain characteristics of the stem cells, such as their potential to differentiate but also to support healing made them a fruitful candidate for lesions in cartilage, a tissue with poor healing capacity. The aim of this editorial is to provide an update on the recent advancements in the field of stem cell therapy for the management of focal cartilage defects. Our goal is to present recent basic science advances and to present the potential of the use of stem cells in novel clinical interventions towards enhancement of the treatment armamentarium for cartilage lesions. Furthermore, we highlight some thoughts for the future of cartilage regeneration and repair and to explore future perspectives for the next steps in the field.
Expert Review of Proteomics · 2024 · 4 citations · open access
Patient-responsive protein biomarkers for cartilage degeneration and repair identified in the infrapatellar fat pad
AbstractOBJECTIVES: Cartilage defects (CDs) are regarded as early manifestation of osteoarthritis (OA). The infrapatellar fat pad (IPFP) is an important mediator in maintaining joint homeostasis, disease progression and tissue repair, with a crucial role of its secreted proteins. Here, we investigate the proteome of the IPFP in relation to clinical status and response to surgical treatment of CDs. METHODS: In order to characterize the proteome of the IPFP, samples from a cohort of 53 patients who received surgical treatment for knee CDs were analyzed with label-free proteomics. Patients were divided based on validated outcome scores for pain and knee function, preoperatively and at 1-year postoperatively, and on MRI assessment of the defect severity, fibrosis and synovitis. RESULTS: Specific proteins were differentially abundant in patients with MRI features and better clinical outcome after CD surgery, including a downregulation of cartilage intermediate layer protein 2 (CILP-2) and microsomal glutathione s-transferase 1 (MGST1), and an upregulation of aggrecan (ACAN), and proteoglycan 4 (PRG4). Pathways related to cell interaction, oxidation and matrix remodeling were altered. CONCLUSION: Proteins in the IPFP that have a function in extracellular matrix, inflammation and immunomodulation were identified as potentially relevant markers for cartilage repair monitoring.
Traumatology and Orthopedics of Russia · 2016 · 2 citations · open access
SURGICAL TREATMENT OF PATIENTS WITH LOCAL DEFECTS OF JOINT SURFACE OF FEMUR CONDYLES (REVIEW)
AbstractThe article provides an overview of the clinical application of basic treatment techniques of local knee cartilage defects: marrow stimulation techniques and autologous osteochondral mosaicplasty. Particular attention authors give the most progressive methods, intensively developing in recent years: the use of cultures of cells capable of chondrogenesis: chondrocytes and mesenchymal stem cells.
Genes and Cells · 2025 · 1 citations · open access
Tissue-engineered and cell-based therapies for cartilage defects
AbstractRegenerative medicine uses cells as therapeutic agents to heal tissues and organs. It is a rapidly evolving area of research worldwide. Cell-based therapy has emerged as a pivotal treatment approach for articular cartilage defects, recognizing the limited regenerative potential of cartilage inherent to its structural biology. Given the inherent challenges associated with the standardization of cell-based drugs compared to conventional pharmaceuticals, the evaluation of their safety and efficacy in preclinical or clinical trials incurs particular considerations. In the majority of cases, autologous chondrocytes and mesenchymal stem/stromal cells derived from various tissues become key components of cell-based therapies currently available for cartilage defects. The cell-based therapies that have been approved for clinical use vary in manufacturing methods, types of cells, and use of matrices as a cell carriers in the finished product. Furthermore, clinicians routinely use a range of surgical techniques to perform a biopsy procedure for the preparation and subsequent implantation of finished cell-based products. Each cell-based treatment option available for patients with cartilage diseases offers a particular indication, benefits, and limitations, underscoring the relevance of comparative analysis of the therapies currently used in clinical practice. This will facilitate clinicians in selecting the most suitable therapy, while researchers may potentially expand the range of diagnoses for such therapies or enhance their efficacy. This review will focus on certain cell-based therapies that have currently arrived at the stages of clinical investigation and have been approved for the treatment of cartilage defects.
An ex vivo human cartilage repair model to evaluate the potency of a cartilage cell transplant
AbstractAbstract Background Cell-based therapies such as autologous chondrocyte implantation are promising therapeutic approaches to treat cartilage defects to prevent further cartilage degeneration. To assure consistent quality of cell-based therapeutics, it is important to be able to predict the biological activity of such products. This requires the development of a potency assay, which assesses a characteristic of the cell transplant before implantation that can predict its cartilage regeneration capacity after implantation. In this study, an ex vivo human cartilage repair model was developed as quality assessment tool for potency and applied to co.donâ s chondrosphere product, a matrix-associated autologous chondrocyte implant (chondrocyte spheroids) that is in clinical use in Germany. Methods Chondrocyte spheroids were generated from 14 donors, and implanted into a subchondral cartilage defect that was manually generated in human articular cartilage tissue. Implanted spheroids and cartilage tissue were co-cultured ex vivo for 12Â weeks to allow regeneration processes to form new tissue within the cartilage defect. Before implantation, spheroid characteristics like glycosaminoglycan production and gene and protein expression of chondrogenic markers were assessed for each donor sample and compared to determine donor-dependent variation. Results After the co-cultivation, histological analyses showed the formation of repair tissue within the cartilage defect, which varied in amount for the different donors. In the repair tissue, aggrecan protein was expressed and extra-cellular matrix cartilage fibers were present, both indicative for a cartilage hyaline-like character of the repair tissue. The amount of formed repair tissue was used as a read-out for regeneration capacity and was correlated with the spheroid characteristics determined before implantation. A positive correlation was found between high level of aggrecan protein expression in spheroids before implantation and a higher regeneration potential after implantation, reflected by more newly formed repair tissue. Conclusion This demonstrated that aggrecan protein expression levels in spheroids before implantation can potentially be used as surrogate potency assay for the cartilage cell transplant to predict its regenerative capacity after implantation in human patients.
An ex vivo human cartilage repair model to evaluate the potency of a cartilage cell transplant
AbstractAbstract Background Cell-based therapies such as autologous chondrocyte implantation are promising therapeutic approaches to treat cartilage defects to prevent further cartilage degeneration. To assure consistent quality of cell-based therapeutics, it is important to be able to predict the biological activity of such products. This requires the development of a potency assay, which assesses a characteristic of the cell transplant before implantation that can predict its cartilage regeneration capacity after implantation. In this study, an ex vivo human cartilage repair model was developed as quality assessment tool for potency and applied to co.donâ s chondrosphere product, a matrix-associated autologous chondrocyte implant (chondrocyte spheroids) that is in clinical use in Germany. Methods Chondrocyte spheroids were generated from 14 donors, and implanted into a subchondral cartilage defect that was manually generated in human articular cartilage tissue. Implanted spheroids and cartilage tissue were co-cultured ex vivo for 12Â weeks to allow regeneration processes to form new tissue within the cartilage defect. Before implantation, spheroid characteristics like glycosaminoglycan production and gene and protein expression of chondrogenic markers were assessed for each donor sample and compared to determine donor-dependent variation. Results After the co-cultivation, histological analyses showed the formation of repair tissue within the cartilage defect, which varied in amount for the different donors. In the repair tissue, aggrecan protein was expressed and extra-cellular matrix cartilage fibers were present, both indicative for a cartilage hyaline-like character of the repair tissue. The amount of formed repair tissue was used as a read-out for regeneration capacity and was correlated with the spheroid characteristics determined before implantation. A positive correlation was found between high level of aggrecan protein expression in spheroids before implantation and a higher regeneration potential after implantation, reflected by more newly formed repair tissue. Conclusion This demonstrated that aggrecan protein expression levels in spheroids before implantation can potentially be used as surrogate potency assay for the cartilage cell transplant to predict its regenerative capacity after implantation in human patients.
Disease module: DeepOracle (Open Targets). Approved indication: ChEMBL drug_indication (max_phase=4). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works, resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
